Analysts Anticipate BioXcel Therapeutics Inc (BTAI) to Announce -$0.48 Earnings Per Share

Equities analysts expect BioXcel Therapeutics Inc (NASDAQ:BTAI) to post ($0.48) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for BioXcel Therapeutics’ earnings. BioXcel Therapeutics reported earnings of ($0.37) per share during the same quarter last year, which suggests a negative year over year growth rate of 29.7%. The business is expected to report its next quarterly earnings report on Monday, May 13th.

On average, analysts expect that BioXcel Therapeutics will report full-year earnings of ($2.21) per share for the current year. For the next fiscal year, analysts forecast that the firm will post earnings of ($3.01) per share. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow BioXcel Therapeutics.

BioXcel Therapeutics (NASDAQ:BTAI) last issued its earnings results on Thursday, March 7th. The company reported ($0.47) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.13).

Several equities analysts have commented on the stock. ValuEngine upgraded shares of BioXcel Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, April 11th. HC Wainwright set a $25.00 price objective on shares of BioXcel Therapeutics and gave the company a “buy” rating in a report on Tuesday, March 26th. Canaccord Genuity set a $21.00 price objective on shares of BioXcel Therapeutics and gave the company a “buy” rating in a report on Friday, March 8th. Finally, Zacks Investment Research downgraded shares of BioXcel Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, January 10th.

Shares of NASDAQ:BTAI traded up $0.03 on Friday, hitting $10.00. The company had a trading volume of 100 shares, compared to its average volume of 40,199. BioXcel Therapeutics has a 1-year low of $2.41 and a 1-year high of $14.79. The company has a market cap of $155.13 million and a P/E ratio of -7.58.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.

Recommended Story: Catch-Up Contributions

Get a free copy of the Zacks research report on BioXcel Therapeutics (BTAI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.